Abstract:<h3 class="article-section__sub-title section1"> Background and purpose</h3><p>Mitochondrial dysfunction plays a role in the progression of cardiovascular diseases including heart failure. 3‐Hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors (statins), which inhibit reactive oxygen species (ROS) synthesis, show cardioprotective effects in chronic heart failure. However, the beneficial role of statins in mitochondrial protection in heart failure remains unclear.</p><h3 class="article-section__sub-title section1"> Experimental approach</h3><p>Rats were treated with Angiotensin II (Ang II) (1.5 mg/kg/day) or co‐administered si<span>m</span>vastatin (oral, 10 mg/kg) for 14 days; and then administration was stopped for the following 14 days. Cardiac structure/function was examined by wheat germ agglutinin staining and echocardiography. Mitochondrial morphology and the numbers of lipid droplets, lysosomes, autophagosomes, and mitophagosomes were determined by transmission electron microscopy. Human cardiomyocytes were stimulated and intracellular ROS and mitochondrial membrane potential (<i>ΔΨm</i>) changes were measured by flow cytometry and JC‐1 staining, respectively. Autophagy and mitophagy‐related and mitochondria‐regulated apoptotic proteins were identified by immunohistochemistry and western blotting. </p><h3 class="article-section__sub-title section1"> Key results</h3><p>Simvastatin significantly reduced ROS production and attenuated the disruption of <i>ΔΨm</i>. Simvastatin induced the accumulation of lipid droplets to provide energy for maintaining mitochondrial function, promoted autophagy and mitophagy, and inhibited mitochondria‐mediated apoptosis. These findings suggest that mitochondrial protection mediated by simvastatin plays a therapeutic role in heart failure prevention by modulating antioxidant status, and promoting energy supplies for autophagy and mitophagy to inhibit mitochondrial damage and cardiomyocyte apoptosis. </p><h3 class="article-section__sub-title section1"> Conclusion and implications</h3><p>Mitochondria play a key role in mediating heart failure progression. Simvastatin attenuated Ang II‐induced heart failure via mitochondrial protection and might provide a new therapy for heart failure prevention.</p>

Mitochondrial protection by simvastatin against angiotensin II‐mediated heart failure

Effects of simvastatin on cardiohemodynamic responses to ischemia–reperfusion in isolated rat hearts

Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.

Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.

Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase

Proteomics of Ischemia and Reperfusion Myocardial Mitochondria by Administration of Simvastatin

Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways

Simvastatin Attenuates Cardiac Fibrosis under Pathophysiological Conditions of Heart Failure with Preserved Left Ventricular Ejection Fraction by Inhibiting TGF-β Signaling

Hesperidin, vanillic acid, and sinapic acid attenuate atorvastatin‐induced mitochondrial dysfunction via inhibition of mitochondrial swelling and maintenance of mitochondrial function in pancreas isolated mitochondria

Effects of Simvastatin on Oxidative Stress of Myocardium and Ventricular Remodeling in Postinfarction Heart Failure Rats

Simvastatin protects heart function and myocardial energy metabolism in pulmonary arterial hypertension induced right heart failure

Endothelial Klf2-Foxp1-TGFβ signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling

Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha

Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion

Enhancement of Autophagy by Simvastatin through Inhibition of Rac1‐mTOR Signaling Pathway

Mitochondrial Protective Mechanism of Simvastatin Protects Against Amyloidï¿½β Peptide-Induced Injury in SH-SY5Y Cells

[Simvastatin Inhibits Hypertension-Induced Cardiac Hypertrophy in Rats Through Activation of Heme Oxygenase-1/Carbon Monoxide Pathway].

The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury

Mitochondrial K ATP channel-mediated autophagy contributes to angiotensin II-induced vascular dysfunction in mice

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts

Simvastatin Improves Mitochondrial Respiration in Peripheral Blood Cells.